Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution

Abstract

Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. These therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination, outweighing potential benefits.